Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07694453

PeriOperative Medicine - Metabolic Inflexibility as a Mechanism for Myocardial Injury After Non-Cardiac Surgery

The goal of this observational study is to learn whether metabolic inflexibility, which means reduced ability of the body to switch between using fats and sugars for energy, is associated with myocardial injury after non-cardiac surgery (MINS) in adults undergoing major elective abdominal cancer surgery.

The main question it aims to answer is:

Does pre-operative metabolic inflexibility predict myocardial injury after non-cardiac surgery (MINS) within the first 72 hours after surgery?

Participants will continue with their usual surgical care and pre-planned CPET (which can measure metabolic flexibility). As part of the study, participants will:

* Have additional blood samples taken before and after surgery * Have an echocardiogram and, where possible, muscle ultrasound * Wear a wrist-worn activity monitor before surgery * Have routine clinical and surgical information collected from their medical records * Receive a follow-up phone call around 90 days after surgery

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The POM-MIMIC study (PeriOperative Medicine - Metabolic Inflexibility as a mechanism for Myocardial Injury after Non-Cardiac Surgery) is a prospective, observational cohort study designed to improve perioperative risk stratification for myocardial injury after non-cardiac surgery (MINS). MINS affects up to 25% of patients undergoing major surgery and significantly increases long and short term mortality (1). Despite its clinical importance, the ability to predict MINS remains limited.

This study aims to evaluate if perioperative metabolic inflexibility, (the impaired ability of cells to adapt fuel usage to demand), is a driver of MINS. The study hypothesises that systemic metabolic dysfunction creates a state of cardiac vulnerability, priming the heart for injury when exposed to the multi-faceted immune/inflammatory and haemodynamic stressors of surgery and anaesthesia.

This study involves a prospective, multicentre observational cohort study of patients undergoing major abdominal cancer surgery. The study investigators will employ a deep, multi-modal phenotyping strategy to characterise each patient's intrinsic "metabolic resilience phenotype", with the goal of describing novel endotypes of MINS. The investigators propose that the endotypes of MINS are:

Immune mediated / inflammatory endotype: Driven by pre-existing inflammation and perioperative immune dysregulation

Metabolic / proteomic endotype: Driven by metabolic inflexibility and may involve direct metabolic injury to cardiomyocytes, lipotoxicity, oxidative stress, and unique troponin fragment signatures

Type II MI / Ischaemic-dominant endotype: Classic supply-demand mismatch (e.g. from intraoperative hypotension), likely amplified in metabolically vulnerable hearts

Mixed phenotype: A combination of the above, reflecting the interaction of metabolic, immune, and haemodynamic stressors

The phenotyping strategy will integrate:

Functional assessment: Cardiopulmonary exercise testing (CPET) to quantify metabolic flexibility via substrate utilisation

Structural assessment: Advanced imaging (CT/ultrasound) to quantify body composition, including myosteatosis and cardiac steatosis, which are markers of metabolic vulnerability

Biological assessment: High-dimensional immunophenotyping, targeted proteomics to identify novel troponin sub-fragment signatures which may reveal if injury is ischaemic, metabolic, or inflammatory, as well as in vitro studies using patient serum on human IPSC-derived cardiomyocytes to test for direct metabotoxicity

An exploratory outcome of reviewing intra-operative data for hypotension, anaesthetic type, and haemodynamics will assess for the ischaemic phenotype.

The study will recruit 300 adult patients undergoing major elective abdominal cancer surgery at UCLH and participating CIPHER-2 sites (Southampton and Plymouth). Participants will undergo routine pre-operative CPET. CPET analysis will derive VO2 peak, anaerobic threshold, metabolic crosscover and substrate utilisation metrics (fat vs carbohydrate oxidation) - the operational measure of metabolic flexibility. They will also undergo routine echocardiography and ultrasound . At this time blood sampling will be taken for targeted and untargeted metabolomics / lipidomics, biobanking of plasma/serum and PBMCs for immunophenotyping. Intra-operatively, haemodynamic monitoring as well as anaesthetic technique will be recorded. Post-operatively, hs-cTnI will be taken on days 1, 2, and 3 to assess for MINS. On days 1, 3, and 5 blood will be taken for biobanking of plasma/serum and PBMCs for immunophenotyping. On day 1 additional biomarker sampling at 24 hours will assess proteomic troponin fragmentation analysis and for mass spectrometry. Outcomes of interest include the incidence of MINS, post operative complications, length of hospital stay, and 90-day recovery metrics. See figure 1 for the participant pathway. A mechanistic substudy (n=150) will investigate inflammatory and immune profiles to explore underlying biological drivers of cardiac susceptibility to stress, these tests will utilise the blood taken for biobanking on days 1, 3, and 5. A further substudy (n=150) will assess if changes in high sensitivity troponin (hs-cTnI levels) measured before and 2 hours after CPET, are associated with the incidence of MINS. An exploratory aim of the project will be to review if there is an association between pre- and post-operative wearable signals (such as activity and heart rate) and MINS. See figure 2 for the conceptual framework of the study.

The data from samples from the MIMICS study will power four interconnected work packages:

WP1 - Immune / inflammatory predictors of MINS (n=150 sub-cohort serum samples)

WP2 - Machine learning integration for MINS prediction

WP3 - Cellular mechanisms and preclinical validation (n=150 sub-cohort serum samples)

WP4 - Targeted proteomic analysis of troponin fragmentation

Through the findings of POM-MIMIC the study investigators hope to redefine understanding of MINS by identifying endotypes. This could lead to immediate clinical benefits by enhancing preoperative risk models through integration of CPET, imaging, and blood testing. These are feasible non-invasive tests that could be rapidly adopted into standard preoperative assessments. This study has translational value as once endotype is categorised, targeted therapies which have been proven to work (such as prehabilitation for metabolic inflexibility) can be employed to reduce perioperative complications and improve outcomes. On a broader scale, this work may inform policy on perioperative cardiac care and guide future clinical trials.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 or over
  • Scheduled for major elective abdominal cancer surgery with planned overnight admission
  • Scheduled for pre-operative CPET
  • Able to provide written informed consent

Exclusion criteria

  • Less than 18 years old
  • Emergency surgery
  • Unable or unwilling to undergo CPET
  • Pregnancy
  • Active sepsis
  • End-stage organ failure (e.g. on dialysis)
  • Participants without the mental capacity to consent
  • Diagnosis of Type 1 Myocardial Infarction meeting the 4th Universal Definition criteria during the immediate pre-operative period. (Note: Added based on MINS definition context)

Treatment and study plan

Pre-operative Metabolic Inflexibility

Other

Pre-operative metabolic inflexibility will be assessed as an observational exposure using data from routine pre-operative cardiopulmonary exercise testing (CPET). CPET-derived measures of substrate utilisation, including fat and carbohydrate oxidation, will be used to evaluate the participant's ability to switch between energy sources during physiological stress. Additional blood-based metabolic, immune, and cardiac biomarker analyses may be used to further characterise metabolic phenotype. No treatment, procedure, or clinical management will be assigned or altered by the study.

Primary outcomes

  1. Development of Myocardial Injury after Non-Cardiac Surgery

    Time frame: From surgery to 72 hours post surgery

    The primary outcome is the number of participants who develop myocardial injury after non-cardiac surgery (MINS) within 72 hours after surgery. MINS means evidence of heart muscle injury after an operation that is not heart surgery. It will be assessed using blood tests for high-sensitivity cardiac troponin I, a protein that is released into the blood when the heart muscle is injured. Blood samples will be taken on postoperative days 1, 2, and 3. Participants will be classified as having MINS if their postoperative troponin result is above the study-defined threshold for myocardial injury and the injury is judged to be related to the perioperative period rather than another clear non-surgical cause.

Secondary outcomes

  1. Clavien-Dindo Complication Grade

    Time frame: From surgery to 30 days after surgery

    Postoperative complications will be classified using the Clavien-Dindo grading system, which grades complications according to the treatment required to manage them. Higher grades indicate more serious complications. The outcome will report the number of participants with major postoperative morbidity, defined as a Clavien-Dindo grade III or higher complication.

  2. Post-Operative Morbidity Survey (POMS)

    Time frame: Postoperative day 7

    Postoperative morbidity will be assessed using the Postoperative Morbidity Survey (POMS), a structured assessment that records whether participants have complications affecting different organ systems after surgery. The outcome will report the number of participants with postoperative morbidity identified by POMS assessment.

  3. Length of Hospital Stay

    Time frame: From surgery up to hospital discharge, an expected average of 7 days after surgery

    Length of hospital stay will be measured as the number of days from the date of surgery to the date the participant is discharged from hospital. This outcome will describe how long participants remain in hospital after their operation.

  4. Days Alive and Out of Hospital at 90 Days

    Time frame: From surgery to 90 days after surgery

    Days alive and out of hospital at 90 days, also known as DAOH90, will be measured as the number of days the participant is alive and not admitted to hospital during the first 90 days after surgery. This outcome reflects postoperative recovery by combining survival, length of initial hospital stay, and any hospital readmissions within 90 days.

Study contacts

Contact information is provided by the study sponsor or research team.

John Whittle, MBBS, PhD

CONTACT

[email protected]

+44 203 447 3390

Rosalyn Hawkins, MBChB

CONTACT

[email protected]

+44 203 447 3390

Sponsors and collaborators

Lead sponsor

University College, London

Other

Registry information

Acronym: POM-MIMICS

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jul 10, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.